About Us
About Vcell

Headquartered in Shanghai, China, Vcell healthcare is a biotech company focused on the development, manufacturing and commercialization of advanced mAb biosimilars in China, with a commitment of bringing affordable world-class biological therapeutics to Chinese patients. It is a joint venture established in 2019 by Celltrion, a leading biopharmaceutical company which has developed world's first mAb biosimilar that has received US FDA/EMA approval, and Nan Fung Group, a renowned conglomerate based in Hong Kong. Vcell has in-licensed several US FDA and EMA approved biosimilar products from Celltrion, including Remsima®,Truxima® and Herzuma®, all have been proven their efficacy and safety through multiple global clinical trials.

Remsima® (infliximab biosimilar) is the world's first mAb biosimilar developed by Celltrion and is a therapeutic agent for autoimmune diseases with including rheumatoid arthritis and ankylosing spondylitis. Remsima® has become one of the bestselling biosimilars worldwide and already secured over 50% of the European market thanks to its advantages such as broad indications among TNF-α inhibitor products, equivalent efficacy and safety to the original drug product, and reasonable price. Remsima® received marketing authorization approval from the European EMA and the US FDA, and, in total, has been launched in over 80 countries.  Remsima® is now undergoing phase III clinical trial in China.

Truxima® (rituximab biosimilar) is the world's first mAb biosimilar in oncology used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. Truxima® has received regulatory approval in Europe and US. It has been launched in Europe since 2017 and gained over 27% market share within a year of entry, and 36% market share in 2018.

Herzuma® (trastuzumab biosimilar) is an anticancer mAb biosimilar used to treat HER2+ breast cancer and gastric cancer that has been proven through multiple global clinical trials. Herzuma® is an effective, more affordable alternative to biologics for the treatment of breast cancer and gastric cancer, and has received regulatory approval in over 40 countries including Europe, US and Japan.

Our Vision
To be China's leading biotech company dedicated to bringing affordable world-class biological therapeutics to Chinese patients
  • Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EMA's approval for INFLECTRA® and Remsima®, respectively, which is the world's first mAb biosimilar to receive approval from a regulatory agency in a developed country. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.

    For more information,please visit http://www.celltrion.com
  • Founded in 1954, Nan Fung Group is a conglomerate based in Hong Kong with global interests in real estate development and investment, life sciences investments, financial investments, hotels and shipping. The Group has established Nan Fung Life Sciences, a global investment platform focusing on life sciences. Leveraging on Nan Fung Group's strong capital base and long term commitment to the area, Nan Fung Life Sciences aims to become the ideal partner for scientists, entrepreneurs, corporations and investors in the life science space. Through direct investments via Pivotal BioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices and diagnostics) and across different development stages, Nan Fung Life Sciences has significant presence in both US and Greater China.

    For more information,please visit http://www.nanfunglifesciences.com
  • Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in venture building in the life sciences industry. Pivotal China closed on $150 million for its first fund and is setting up an additional $50 million equivalent RMB fund. Its investment strategy is centered on identifying promising innovative products and technologies and bringing them to build new companies in China. The Pivotal team includes experienced life science investors and entrepreneurs with a track record of venture building and scientific acumen.

    For more information,please visit http://www.pivotalbiovp.cn/
Contact Us
Suite1202B, 12F, Tower 2, 1239 Century Avenue, Century Metropolis, Pudong District, Shanghai, PRC
Email: dingsai@vcellhealthcare.com /Career: HR@vcellhealthcare.com/Patient Recruitment: clinicaltrial@vcellhealthcare.com
©2019 Vcell Healthcare Limited 沪ICP备19024936号
Power By : A+T